Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Exelixis (EXEL) PT Raised to $30 at Oppenheimer
August 6, 2021 10:36 AM EDTOppenheimer analyst Silvan Tuerkcan raised the price target on Exelixis (NASDAQ: EXEL) to $30.00 (from $27.00) while maintaining an Outperform rating.
The analyst commented, "EXEL provided 2Q financial results featuring record Cabo sales of $284.2M with continued uptake of nivo + cabo in 1L RCC following FDA... More
Exelixis (EXEL) Tops Q2 EPS by 30c
August 5, 2021 4:25 PM EDTExelixis (NASDAQ: EXEL) reported Q2 EPS of $0.37, $0.30 better than the analyst estimate of $0.07. Revenue for the quarter came in at $385.2 million versus the consensus estimate of $298.16 million.
GUIDANCE:
Exelixis sees FY2021 revenue of $1.3-1.4 billion, versus the consensus of $1.23... More
